( RASTATR is also contraindicated in pati...)Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology,Health

Bleeding is the most common complication encountered during therapy with AGGRASTATR. Administration of AGGRASTATR is associated with an increase in bleeding events classified as both major and minor bleeding events, by criteria developed by the Thrombolysis in Myocardial Infarction Study group (TIMI). Most major bleeding associated with AGGRASTATR occurs at the arterial access site for cardiac catheterization. Fatal bleedings have been reported. AGGRASTATR should be used with caution in patients with platelet count less than 150,000/mm3, in patients with hemorrhagic retinopathy and in patients in chronic hemodialysis. Because AGGRASTATR inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis. The safety of AGGRASTATR when used in combination with thrombolytic agents has not been established. During therapy with AGGRASTATR, patients should be monitored for potential bleeding. When bleeding cannot be controlled with pressure, infusion of AGGRASTATR and heparin should be discontinued.

About Medicure Inc.

Medicure is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. The Company's solid position in this field is highlighted by the following:

* Lead compound MC-1 in pivotal Phase 3 study for FDA approval * Four positive Phase 2 trials completed with MC-1 * FDA Fast Track designation for MC-1 * U.S. rights to AGGRASTATR Injection (tirofiban hydrochloride) * Combination of MC-1 and lisinopril (MC-4232) completed Phase 2 * Dual action antithrombotic, MC-45308, with positive preclinical results

Medicure also has a medicina
'"/>